Tier 4 — mechanistic

Apigenin Inhibits Pancreatic Stellate Cell Activity in Pancreatitis

Amy A. Mrazek, Laura J. Porro, Vandanajay Bhatia, Miriam Falzon, Heidi Spratt, Jia Zhou, Celia Chao, Mark R. Hellmich
Journal of Surgical Research 2015 196(1):8-16

Bibliography

PubMed
PMID 25799526
PubMed Central
PMC4430404
DOI
10.1016/j.jss.2015.02.032

Study snapshot

DesignIn vivo mouse plus in vitro human-cell study
ModelCerulein-induced recurrent acute pancreatitis in mice and human pancreatic stellate cells
Sample
InterventionApigenin 50 μg/mouse by oral gavage daily after pancreatitis induction; cultured-cell apigenin experiments
DurationFour weeks in the mouse model
EndpointsPancreatic fibrosis; Acinar preservation; Stellate-cell viability and apoptosis; Collagen 1A1; Fibronectin; TGF-β and IL-6

What the study showed, in plain terms

This study explored whether apigenin can slow fibrotic remodeling during repeated pancreatic injury.

Key findings

Apigenin reduced fibrosis and preserved acinar tissue in mice, while inhibiting pancreatic stellate-cell viability and profibrotic gene expression.

What this study can and cannot tell us

The findings are preclinical and do not demonstrate prevention or treatment of chronic pancreatitis in humans.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology